Search Results for "drug"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for drug. Results 2201 to 2210 of 2586 total matches.

Choice of Contraceptives

   
The Medical Letter on Drugs and Therapeutics • May 15, 2023  (Issue 1676)
irritation; must be reapplied with each act of intercourse Withdrawal 20% 4% No drugs or devices High ...
Intrauterine devices (IUDs) and the etonogestrel implant are the most effective reversible contraceptive methods available. Hormonal oral contraceptives, patches, rings, and injectables are also effective in preventing pregnancy. When used alone, barrier and behavioral methods generally have higher failure rates than other methods (see Table 1). Selection of a contraceptive method is usually based on patient-specific factors and personal preference
Med Lett Drugs Ther. 2023 May 15;65(1676):73-80   doi:10.58347/tml.2023.1676a |  Show IntroductionHide Introduction

Nirsevimab (Beyfortus) for Prevention of Severe RSV Disease in Young Children

   
The Medical Letter on Drugs and Therapeutics • Sep 18, 2023  (Issue 1685)
disease through their second RSV season. Nirsevimab is the first drug to be approved for protection ...
The FDA has approved nirsevimab-alip (Beyfortus – AstraZeneca/Sanofi), a long-acting monoclonal antibody, for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants born during or entering their first RSV season, and in children ≤24 months old who are at increased risk for severe RSV disease through their second RSV season. Nirsevimab is the first drug to be approved for protection of all infants during their first RSV season.
Med Lett Drugs Ther. 2023 Sep 18;65(1685):145-7   doi:10.58347/tml.2023.1685a |  Show IntroductionHide Introduction

Comparison Table: Some Nasal Sprays for Seasonal Allergic Rhinitis (online only)

   
The Medical Letter on Drugs and Therapeutics • Mar 31, 2025  (Issue 1725)
Comparison Table: Some Nasal Sprays for Seasonal Allergic Rhinitis Drug Some Formulations OTC/Rx ...
View the Comparison Table: Some Nasal Sprays for Seasonal Allergic Rhinitis
Med Lett Drugs Ther. 2025 Mar 31;67(1725):e58-63   doi:10.58347/tml.2025.1725c |  Show IntroductionHide Introduction

In Brief: Taliglucerase (Elelyso) for Gaucher Disease

   
The Medical Letter on Drugs and Therapeutics • Jul 09, 2012  (Issue 1394)
The Medical Letter® On Drugs and Therapeutics Volume 54 (Issue 1394) July 9, 2012 ...
The FDA has approved taliglucerase alfa (ta lee gloo´ se rays; Elelyso – Pfizer/Protalix), a recombinant form of glucocerebrosidase, for treatment of adults with Type 1 Gaucher disease. These patients have a genetic deficiency of the lysosomal enzyme glucocerebrosidase that leads to accumulation of glucosylceramide in the lysosomes of reticuloendothelial cells, primarily in the liver, spleen and bone marrow.1Taliglucerase is the third form of the enzyme to become available in the US. Imiglucerase (Cerezyme) and velaglucerase (Vpriv) are produced in mammalian cell lines. Taliglucerase is...
Med Lett Drugs Ther. 2012 Jul 9;54(1394):56 |  Show IntroductionHide Introduction

In Brief: Merilog — A NovoLog Biosimilar

   
The Medical Letter on Drugs and Therapeutics • Mar 11, 2025  (Issue 5101)
pens and 10-mL multidose vials containing 100 units/mL of insulin aspart. The drug should ...
The FDA has approved Merilog (Sanofi), a biosimilar to rapid-acting insulin aspart (NovoLog), for treatment of patients with type 1 or type 2 diabetes. Merilog is the first rapid-acting insulin biosimilar product to become available in the US.
Med Lett Drugs Ther. 2025 Mar 11;67(5101):1   doi:10.58347/tml.2025.5101a |  Show IntroductionHide Introduction

Ethanolamine Oleate For Esophageal Varices

   
The Medical Letter on Drugs and Therapeutics • Nov 03, 1989  (Issue 804)
The Medical Letter  On Drugs and Therapeutics www.medletter.com Published by The Medical ...
Endoscopic injection of sclerosing agents is now widely accepted as a primary treatment for bleeding esophageal varices (J Terblanche et al, N Engl J Med, 320:1393, 1469, May 25 and June 1, 1989). Ethanolamine oleate 5% (Ethamolin - Glaxo), a sclerosing agent that has been available in Canada and abroad for many years, was recently approved for this indication by the US Food and Drug Administration (FDA).
Med Lett Drugs Ther. 1989 Nov 3;31(804):99-100 |  Show IntroductionHide Introduction

BCG For Bladder Cancer

   
The Medical Letter on Drugs and Therapeutics • Apr 05, 1991  (Issue 841)
The Medical Letter  On Drugs and Therapeutics www.medletter.com Published by The Medical ...
BCG Live (TheraCys - Connaught) and BCG Vaccine U.S.P. (TiceBCG - Organon), freeze-dried suspensions of an attenuated strain of Mycobacterium bovis, were recently approved by the US Food and Drug Administration for intravesical treatment of primary or relapsed carcinoma in situ of the bladder, with or without associated papillary tumors. BCG is not recommended for treatment of papillary tumors occurring alone.
Med Lett Drugs Ther. 1991 Apr 5;33(841):29-30 |  Show IntroductionHide Introduction

Autologous Bone marrow Transplantation For Advanced Breast Cancer

   
The Medical Letter on Drugs and Therapeutics • May 03, 1991  (Issue 843)
The Medical Letter  On Drugs and Therapeutics www.medletter.com Published by The Medical ...
The prognosis in breast cancer is generally poor for women with unresectable, locally advanced disease (inflammatory cancer or more than 10 positive lymph nodes) and for those with metastases. Autologous bone marrow transplantation - removing bone marrow from multiple sites under general anesthesia, giving high-dose chemotherapy with or without total body radiation, and reinfusing the bone marrow intravenously - is being tried in some of these patients.
Med Lett Drugs Ther. 1991 May 3;33(843):39-40 |  Show IntroductionHide Introduction

Tetramune - A Combined Vaccine For Infants

   
The Medical Letter on Drugs and Therapeutics • Nov 12, 1993  (Issue 909)
The Medical Letter  On Drugs and Therapeutics www.medletter.com Published by The Medical ...
The number of immunizations recommended for infants and young children has increased in recent years with the addition of vaccines to prevent Haemophilus influenzae type b infection and hepatitis B (Medical Letter, 33:5, 1991; 34:69, 1992). Now the US Food and Drug Administration has licensed a new vaccine for infants (Tetramune - Lederle-Praxis) that combines a traditional diphtheria, tetanus, and pertussis vaccine (DTP; Tri-Immunol) with a vaccine against Haemophilus influenzae type b (HibTiter).
Med Lett Drugs Ther. 1993 Nov 12;35(909):104-5 |  Show IntroductionHide Introduction

Palivizumab for Prevention of RSV Infection

   
The Medical Letter on Drugs and Therapeutics • Jan 01, 1999  (Issue 1043)
The Medical Letter  On Drugs and Therapeutics www.medletter.com Published by The Medical ...
The US FDA has approved use of palivizumab for prevention of respiratory syncytial virus (RSV) infection in high-risk infants and children.
Med Lett Drugs Ther. 1999 Jan 1;41(1043):3-4 |  Show IntroductionHide Introduction